GlobeNewswire

Server Technology's HDOT Rack Mount PDU Named a 2018 DCS Award Finalist For Alternating Phase Technology

Dela

Unique Product Innovation Receives Judge's Nod for Server Rack PDU Product of the Year

RENO, Nev., April 17, 2018 (GLOBE NEWSWIRE) -- Server Technology, a brand of Legrand and a leading provider of intelligent Rack Power Distribution Units a.k.a rack PDU(s), today announced that it has been selected as a finalist in the 2018 DCS Awards. Server Technology has been shortlisted in the Data Centre PDU Product of the Year category for their High Density Outlet Technology (HDOT) Rack PDUs with Alternating Phase outlet technology. Today's announcement marks the fifth year that Server Technology has been singled out for product excellence by the DCS Awards panel, winners are selected based solely on public votes received, with votingopen until 11 May.

The DCS Awards, in association with Datacentre Solutions magazine, are designed to reward the product designers, manufacturers, suppliers and providers operating in the data centre arena, recognising the achievements of the vendors and their business partners alike. Continually, DCS Awards judges have singled out Server Technology's server rack power strips as providing the industry with unique benefits above and beyond standard rack mount PDU solutions.

For the 2018 DCS Awards, Server Technology's patented Alternating Phase outlet technology on the High Density Outlet Technology (HDOT) PDUs stood out from among competitive offerings with its simplified load balancing and cable management for 3-Phase PDUs that distribute phased power on a per receptacle basis. This innovation provides tangible benefits in the form of shorter cable runs that result in better airflow, easier load balancing, and overall greater efficiencies.

"Providing Alternating Phase technology at the PDU level provides our customers with a highly customized power solution, specifically tailored to meet their individual needs. Testament to its success is the fact that HDOT is our fastest growing PDU in the market, doubling in quantity shipped year over year since 2014," said Travis Irons, Director of Engineering at Server Technology. "We are honored that our customized power solutions continue to be validated by technology professionals as among the best in the industry."

In addition to the 2018 finalist status, DCS Awards named the company:

  • 2017 "Individual of the Year" DCS Award for VP of International Sales, Marc Marazzi
  • 2016 "Data Centre PDU Product of the Year" DCS Award for HDOT
  • 2015 and 2014 "Data Centre Management Product of the Year" DCS Award for Sentry Power Manager (SPM)

Winners will be announced at a gala evening at the Grange, St Paul's Hotel, London on 24 May 2018.

For more information please contact lucy.holloway@servertech.com or visit www.servertech.com.

About Server Technology

Server Technology's power strategy experts are trusted to provide Rack PDU solutions for demanding data centers worldwide ranging from small technology startups to Fortune 100 powerhouses. Over 60,000 customers around the world rely on our rack power distribution units to increase density, facilitate capacity planning, improve power monitoring, and drive efficiency. Because power is all we do, you will find us in the best cloud and co-location providers, forward thinking labs and telecommunications operations. Server Technology customers consistently rank us as providing the highest quality PDU(s), the best customer support and most valuable innovation. Let us show you; we have over 12,000 PDU configurations to fit every data center need and 90% of our PDU(s) are shipped within 10 days. Only with Server Technology will customers Stay Powered, Be Supported and Get Ahead. www.servertech.com

About Legrand and Legrand, North and Central America

Legrand is a global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for use in commercial, industrial, and residential markets makes it a benchmark for customers worldwide. Innovation for a steady flow of new products with high added value is a prime vector for growth, including, in particular, connected devices stemming from Legrand's global Eliot (Electricity and IoT) program. Legrand reported sales of $6.2 billion(USD) in 2017. Legrand has a strong presence in North and Central America, with a portfolio of well-known market brands and product lines that includes AFCO Systems, C2G, Cablofil, Chief, Da-Lite, Electrorack, Finelite, Luxul, Middle Atlantic Products, Milestone AV, Nuvo, OCL, On-Q, Ortronics, Pass & Seymour, Pinnacle, Projecta, QMotion, Quiktron, Raritan, Sanus, Server Technology, Solarfective, Vaddio, Vantage, Wattstopper, and Wiremold. Legrand is listed on Euronext Paris and is a component stock of indexes including the CAC40, FTSE4Good, MSCI World, ASPI, Corporate Oekom Rating, and DJSI (ISIN code FR0010307819). www.legrand.us

For more information, contact:
Betsey Rogers
Public Relations
BridgeView Marketing
1-603-821-0809
betsey@bridgeviewmarketing.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Server Technology via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum